560 related articles for article (PubMed ID: 29643228)
41. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
[TBL] [Abstract][Full Text] [Related]
42. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
43. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
44. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
45. Inhibitors of MDM2 and MDMX: a structural perspective.
Riedinger C; McDonnell JM
Future Med Chem; 2009 Sep; 1(6):1075-94. PubMed ID: 21425995
[TBL] [Abstract][Full Text] [Related]
46. Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.
Luo HJ; Si DJ; Sun XJ; Wang MY; Yang YB; Wang B; Wen HM; Li W; Liu J
Eur J Med Chem; 2023 Apr; 252():115282. PubMed ID: 36989812
[TBL] [Abstract][Full Text] [Related]
47. Mdmx and Mdm2: brothers in arms?
Marine JC; Jochemsen AG
Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
[TBL] [Abstract][Full Text] [Related]
48. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
[TBL] [Abstract][Full Text] [Related]
49. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Long J; Parkin B; Ouillette P; Bixby D; Shedden K; Erba H; Wang S; Malek SN
Blood; 2010 Jul; 116(1):71-80. PubMed ID: 20404136
[TBL] [Abstract][Full Text] [Related]
50. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
51. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models.
Ng SY; Yoshida N; Christie AL; Ghandi M; Dharia NV; Dempster J; Murakami M; Shigemori K; Morrow SN; Van Scoyk A; Cordero NA; Stevenson KE; Puligandla M; Haas B; Lo C; Meyers R; Gao G; Cherniack A; Louissaint A; Nardi V; Thorner AR; Long H; Qiu X; Morgan EA; Dorfman DM; Fiore D; Jang J; Epstein AL; Dogan A; Zhang Y; Horwitz SM; Jacobsen ED; Santiago S; Ren JG; Guerlavais V; Annis DA; Aivado M; Saleh MN; Mehta A; Tsherniak A; Root D; Vazquez F; Hahn WC; Inghirami G; Aster JC; Weinstock DM; Koch R
Nat Commun; 2018 May; 9(1):2024. PubMed ID: 29789628
[TBL] [Abstract][Full Text] [Related]
52. MDM2/MDMX inhibitor peptide: WO2008106507.
Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
[TBL] [Abstract][Full Text] [Related]
53. MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.
Marine JC; Jochemsen AG
Cold Spring Harb Perspect Med; 2016 Jul; 6(7):. PubMed ID: 27371671
[TBL] [Abstract][Full Text] [Related]
54. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
56. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
Cai X; Yuan ZM
J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
[TBL] [Abstract][Full Text] [Related]
57. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
58. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
59. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
Kannan S; Partridge AW; Lane DP; Verma CS
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
[TBL] [Abstract][Full Text] [Related]
60. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling.
Venkatesh D; O'Brien NA; Zandkarimi F; Tong DR; Stokes ME; Dunn DE; Kengmana ES; Aron AT; Klein AM; Csuka JM; Moon SH; Conrad M; Chang CJ; Lo DC; D'Alessandro A; Prives C; Stockwell BR
Genes Dev; 2020 Apr; 34(7-8):526-543. PubMed ID: 32079652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
